Review Article
Pulmonary Hypertension Secondary to COPD
Table 7
Baseline characteristics of the patients who received pulmonary vasodilators in the published studies of such drugs in COPD.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
mg: milligrams, BID: twice a day, TID: three times a day, vs: versus, N: total number of patients who received the study drug, N with PH: number of patients with pulmonary hypertension, PH: pulmonary hypertension, sPAP: systolic pulmonary artery pressure estimated by echocardiography, mPAP: mean pulmonary artery pressure measured by right heart catheterization, CO: cardiac output, CI: cardiac index, PVR: pulmonary vascular resistance, FEV1: forced expiratory volume in the first second, TLC: total lung capacity, DLCO: diffusing capacity for carbon monoxide, SpO2: oxygen saturation by pulse oximetry, PaO2: arterial oxygen tension, PaCO2: arterial carbon dioxide tension, 6MWD: six-minute walk distance. *resting PH defined as mPAP > 25 mm Hg or ECHO estimated sPAP > 40 mm Hg unless specified otherwise—see below: †PH was defined as estimated sPAP > 30 mm Hg without adding central venous pressure (CVP). ‡Estimated sPAP without adding CVP. If CVP is assumed to be 5 mm Hg, this gives a sPAP of 37 mm Hg which amounts to a mPAP of 24 mm Hg based on the prediction equation 0.6 × sPAP + 2 = mPAP [113]. §Calculated mPAP based on the prediction equation 0.6 × sPAP + 2 = mPAP [113]. |